Aarti Drugs' Q2 FY 2025-26 Quarterly Results

Result Summary

• Aarti Drugs Ltd reported a 10.5% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 8.8%.
• Its expenses for the quarter were up by 9.8% QoQ and 7.0% YoY.
• The net profit decreased 16.3% QoQ and increased 29.2% YoY.
• The earnings per share (EPS) of Aarti Drugs Ltd stood at 4.95 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aarti Drugs Ltd is a prominent player in the pharmaceutical and healthcare industry, primarily engaged in the manufacturing of active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company is based in India and has established a significant presence in both domestic and international markets. Aarti Drugs Ltd is known for its robust product portfolio, which includes a wide range of therapeutic categories such as antibiotics, anti-protozoal, anti-inflammatory, and anti-diabetic drugs. The company has consistently focused on research and development to enhance its product offerings and maintain competitive advantage in the industry. Aarti Drugs Ltd has been recognized for its commitment to quality and compliance with international regulatory standards. Any recent major developments about the company are not available for inclusion in this report.

Revenue

In the second quarter of the financial year 2026 (Q2FY26), Aarti Drugs Ltd reported a total income of ₹652.88 crores. This represents a quarter-over-quarter (QoQ) increase of 10.5% compared to the previous quarter (Q1FY26), where the total income was ₹590.82 crores. Additionally, there is a year-over-year (YoY) growth of 8.8% in total income compared to the same quarter in the previous financial year (Q2FY25), which recorded a total income of ₹599.81 crores. The revenue growth highlights the company's ability to generate increased sales and possibly expand its market reach during this period.

Profitability

Aarti Drugs Ltd's financial performance in terms of profitability shows various dynamics in Q2FY26. The company recorded a profit before tax of ₹60.41 crores, which is an increase of 18.2% QoQ from ₹51.11 crores in Q1FY26, and a notable YoY increase of 31.7% from ₹45.88 crores in Q2FY25. However, the profit after tax for Q2FY26 was ₹45.16 crores, reflecting a decrease of 16.3% QoQ from ₹53.97 crores in Q1FY26, but a YoY increase of 29.2% from ₹34.96 crores in Q2FY25. The company reported earnings per share of ₹4.95, with similar percentage changes as profit after tax. The tax figure for Q2FY26 was ₹15.25 crores, which contrasts with a tax refund of ₹2.86 crores in Q1FY26 and a tax expense of ₹10.92 crores in Q2FY25, indicating a significant change in tax liabilities.

Operating Metrics

The total expenses for Aarti Drugs Ltd in Q2FY26 amounted to ₹592.47 crores, marking an increase of 9.8% QoQ from ₹539.71 crores in Q1FY26, and a 7.0% YoY increase compared to ₹553.93 crores in Q2FY25. This consistent rise in expenses aligns with the increase in total income, suggesting operational expansion or increased input costs. The company's capacity to manage expenses while achieving revenue growth is reflected in its profitability metrics. The data provided does not include specific financial ratios such as the P/E ratio, debt-to-equity ratio, or current ratio. Therefore, further analysis would be required to gain a comprehensive understanding of the company's operational efficiency and financial health.